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Abstract
Transcriptional and splicing anomalies have beenobserved in intron 8 of theCASP8 gene (encoding procaspase-8) in association
with cutaneous basal-cell carcinoma (BCC) and linked to a germline SNP rs700635. Here, we show that the rs700635[C] allele,
which is associated with increased risk of BCC and breast cancer, is protective against prostate cancer [odds ratio (OR) = 0.91,
P = 1.0 × 10−6]. rs700635[C] is also associated with failures to correctly splice out CASP8 intron 8 in breast and prostate tumours
and in corresponding normal tissues. Investigation of rs700635[C] carriers revealed that they have a human-speciﬁc short
interspersed element-variable number of tandem repeat-Alu (SINE-VNTR-Alu), subfamily-E retrotransposon (SVA-E) inserted
into CASP8 intron 8. The SVA-E shows evidence of prior activity, because it has transduced some CASP8 sequences during
subsequent retrotransposition events. Whole-genome sequence (WGS) data were used to tag the SVA-E with a surrogate SNP
rs1035142[T] (r2 = 0.999), which showed associations with both the splicing anomalies (P = 6.5 × 10−32) and with protection
against prostate cancer (OR = 0.91, P = 3.8 × 10−7).
Introduction
CASP8 encodes an initiator caspase that functions in the extrinsic
pathway of apoptosis, controlled by death receptors of the tu-
mour necrosis factor receptor superfamily. Somatic deletions
and pointmutations of CASP8 have been observed in several can-
cer types including colorectal, head and neck, gastric cancer and
neuroblastoma (1,2). Germline sequence variants in and near the
CASP8 gene have been implicated in susceptibility to several dif-
ferent cancer types including breast cancer, melanoma, basal-
cell carcinoma (BCC) and chronic lymphocytic leukaemia (3–7).
We have sequenced the genomes of 8383 Icelanders and im-
puted the genotypes of 150 656 chip-typed, long-range phased
Icelanders and their relatives. This allows us to search for asso-
ciations between over 25 million sequence variants and a broad
range of phenotypes (7,8). Recently, we reported an association
between variants near CASP8 and BCC. One of the BCC risk var-
iants, rs700635[C], is strongly associated with transcriptional
and splicing anomalies involving CASP8 (7). Here, we show that
rs700635[C] tags an SVA-E retrotransposon that is inserted into
intron 8 of the CASP8 gene and is linked to the observed splicing
anomalies. Surprisingly, we ﬁnd that insertion of the SVA-E is
also associated with protection against prostate cancer.
Results
We previously found that the BCC risk variant rs700635[C] (Ice-
landic population allele frequency: 0.299) is associated with
impaired splicing of CASP8 intron 8. A highly correlated variant
(r2 = 1 in Iceland), rs1830298 has been shown to be associated
with breast cancer (9) and we conﬁrmed this effect for rs700635
[C] in 5534 breast cancer patients and 309 172 controls from Ice-
land [odds ratio (OR) = 1.08, P = 0.0035, 95% conﬁdence interval
(CI): 1.02–1.13]. Given the potential formulti-cancer susceptibility
conferred by this variant, we tested its association with other
forms of cancer, using Icelandic Cancer Registry (ICR) records.
We saw a signal suggesting that rs700635 is associated with pros-
tate cancer (Table 1) based on 5274 cases and 97 905 controls.
However the OR indicated that, unlike for BCC and breast cancer,
the rs 700635[C] allele appeared to protect against prostate cancer
(OR = 0.92, P = 0.0018, 95%CI: 0.87–0.97).We sought to conﬁrm this
by examining prostate cancer genome-wide association study
chip data from the Netherlands and by single-track genotyping
rs700635 in replication samples from the USA, Spain, Romania
and the UK, a total of 5245 non-Icelandic prostate cancer cases
and 9971 controls (Table 1). The replication sample set corre-
sponds to an effective sample size of 6441 cases and 6441 con-
trols, providing an estimated power of 87% to reproduce the
association. The initial ﬁnding was conﬁrmed in the replication
sample set (OR = 0.90, P = 1.4 × 10−4, 95% CI: 0.85–0.94). Overall
evidence for the association, including the Icelandic sample,
was OR = 0.91, P = 1.0 × 10−6, 95% CI: 0.88–0.95 and was without
signiﬁcant heterogeneity (Table 1). The published (9) breast can-
cer risk allele, rs1830298[C] showed similar protection against
prostate cancer in Iceland (OR = 0.92, P = 0.0018) as would be
expected from the strong correlation between the two variants.
In blood and sun-exposed skin tissues, rs700635[C] is asso-
ciatedwith the presence of RNA isoformsofCASP8 inwhich intron
8 fails to splice out correctly and contain a variant exon unique to
the NM_033358 transcript. These RNA isoforms are of interest be-
cause they conceivably could lead to attenuated caspase-8 signal-
ling (7). We analysed RNA-sequencing (RNA-seq) data from 93
samples in the Genotype-Tissue Expression (GTEx) project and
found that rs700635[C] is similarly associatedwith a signiﬁcant re-
tention of CASP8 sequences mapping to the 5′ half of intron 8 in
bothnormal prostate and breast tissues (Fig. 1). Amodest decrease
in expression of the CASP8major exons was also shown in breast
although not in prostate tissue. We also noted the presence of
RNA-seq reads in the 3′ end of intron 7, as we had previously
seen in sun-exposed skin (7). In order to determinewhether simi-
lar splicing anomalies are present in tumours of the breast and
prostate, we examined the cancer genome atlas (TCGA) RNA-seq
data. Indeed, both tumour types showed highly signiﬁcant reten-
tion of intron 8 sequences in association with rs700635[C] (P = 8.3
× 10−80 and 1.4 × 10−34 for breast and prostate tumours, respective-
ly; Supplementary Material, Fig. S1).
In both our RNA-seq data and our whole-genome DNA se-
quencing data, we observed very low read coverage over a
∼2.8 kb region at the 3′ end of intron 8. The region concerned is
highly repetitive and GC rich. Using whole-genome sequence
(WGS) data from 5253 individuals [from whom the majority
of samples were prepared using Illumina’s polymerase chain re-
action (PCR)-free or TruSeq Nano sample preparation methods,
which are less susceptible to GC bias than older HiSeq methods]
we detected a copy number variation at this location,with signiﬁ-
cantly higher read counts being correlated with the presence of
rs700635[C] (Fig. 2A). Further examination revealed that the region
contains a polymorphic insertion/deletion of a 2792 bp short
interspersed element-variable number of tandem repeat-Alu
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(SINE-VNTR-Alu), subfamily-E retrotransposon (SVA-E, Fig. 2B).
TheSVA-E retrotransposon,whenpresent, is in the opposite orien-
tation to the CASP8 gene.
We used DNA sequence reads with paired ends near the SVA-
E insertion site breakpoints to detect the presence of the retro-
transposon and assess its association with rs700635 genotype.
There was a strong association between reads that cross the
(empty) insertion site and the rs700635[A] allele (Fig. 2C, P << 2 ×
10−16). Similarly, reads that cross from native CASP8 sequence
into SVA-E retrotransposon sequence were strongly associated
with the rs700635[C] allele (Supplementary Material, Fig. S2).
Thus, rs700635[C] is associated with protection against prostate
cancer, failure to correctly splice CASP8 intron 8, and with the
presence of the SVA-E retrotransposon in the intron.
We characterized the insertion site of the CASP8 SVA-E on
chromosome 2 (Fig. 3). The SVA-E is inserted 20 bp to the right
of the NM_033358 variant exon and extends to within 112 bp of
exon 9. The insertion is ﬂanked by a 10 bp target site duplication
(TSD). Incidentally, we noted some anomalies in the correlation
between reads spanning the left and the right ends of the SVA-
E insertion in certain individuals. Upon further investigation, it
became evident that a copy of the SVA-E has transposed out of
the CASP8 gene and inserted into chromosome 19 (±6 bp around
chr19:46833489, Fig. 3). It appears that when this transposition
event occurred, the SVA-E transduced with it a 288 bp stretch of
3′ ﬂanking sequence from the CASP8 gene (which, due to the
orientation of the SVA-E, is to the left of the insertion site,
Fig. 3). SVA elements are known to occasionally transduce
3′ ﬂanking sequences during transposition (10). For the CASP8
element, the probable directionality of transposition was estab-
lished by the observations that (i) the transduced segment exists
as native chr2 sequence on copies of chromosome 2which do not
contain the SVA-E insertion, (ii) the transduced segment does not
occur on chr19 except in associationwith the SVA-E insertion, (iii)
the chr2 TSD comprises the ﬁrst 10 bp of the transduced segment,
(iv) on chr19, the transduced segment is followed by a short polyA
tract then bya TSD comprised of native chr19 sequence and (v) the
polyA tract is preceded in the transduced segment by an AATAAA
polyadenylation sequence comprised of native CASP8 intron 8 se-
quence. Taken together, these observations suggest that a tran-
script arising at the 5′ end of the chr2 SVA-E failed to terminate
at the internal SVA-E polyadenylation site, but rather ran on into
native chr2 sequenceuntil it encountered a fortuitouspolyA signal
on the reverse stand of CASP8 intron 8 sequence. The resulting
RNA gained a short polyA tail then retrotransposed into the site
on chr19, creating a new TSD at the insertion site. This indicates
that the SVA-E insertion in the CASP8 gene has been active and
capable of retrotransposition. Ongoing activity of the SVA-E
might interfere with the correct functioning of the CASP8 gene.
We wanted to impute CASP8 SVA-E insertion genotypes into
our set of long-range phased Icelanders (11–13) and to genotype
the SVA-E in non-Icelandic populations. Even though the associ-
ationbetween the SVA-E retrotransposonand rs700635[C] is highly
signiﬁcant, the correlation is not perfect (we estimate the r2 as 0.71
in the Icelandic population). Genotyping the SVA-E directly is com-
plicated by the chromosome 19 retrotransposition/transduction
event described above. Nevertheless, by restricting genotype
calls to information derived from insertion site-spanning and
right end read pairs, we were able to determine SVA-E genotype
likelihoods for a set of 8434 whole-genome sequenced individuals
and impute these SVA-E genotypes for 150 656 chip-typed, long-
range phased Icelanders and their relatives (see the ‘Materials
andMethods’ section).We then searched for a SNP allele or haplo-
type that tags the presence of the SVA-E with high conﬁdence.WeT
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identiﬁed rs1035142[T] (MAF = 0.38), which has an r2 of 0.999 with
the SVA-E insertion in the Icelandic population. Inorder tovalidate
this tagging SNP and see whether the linkage disequilibrium (LD)
relation holds in non-Icelandic populations, we generated a Cen-
taurus single-track assay for rs1035142 and a PCR assay to detect
the SVA-E directly (see the ‘Materials and Methods’ section). The
presence of the SVA-E showed perfect LD with rs1035142[T] in a
set of 184 individuals of European ancestry from the USA (r2 = 1,
P << 2 × 10−16). Accordingly, we concluded that rs1035142[T] is a
reasonable surrogate for the SVA-E-positive (SVA-E[pos]) genotype
in populations of European ancestry.
We then re-assessed the association with prostate cancer
using knowledge of the SVA-E and its surrogate SNP. As expected,
the SVA-E[pos] and rs1035142[T] genotypes gave similar associ-
ation results for prostate cancer in the Icelandic population sam-
ple (P = 0.0069 and 0.0064, respectively). Inclusion of non-Icelandic
replication sample genotypesyielded an overall result of OR= 0.91,
P = 3.8 × 10−7 (cf. OR= 0.91, P = 1.0 × 10−6 for rs700635[C], Table 1). In
conditional analysis, the association with rs1035142[T] remained
nominally signiﬁcant when adjusted for the effect of rs700635
(Padj = 0.044).
Next, we examined the association of the SVA-E and its surro-
gate rs1035142[T] with the transcriptional and splicing anomalies
that were observed in CASP8 intron 8. Using WGS imputed geno-
types and Icelandic RNA-seq data from 628 blood samples, we
scanned the region surrounding rs700635 to identify variants
that correlate most strongly with the retention of intron 8 se-
quences. The SVA-E and a cluster of correlated variants, including
rs1035142, were the most signiﬁcantly associated with intron re-
tention (P = 2.2 × 10−32 for the SVA-E, P = 6.5 × 10−32 for rs1035142,
Supplementary Material, Fig. S3A). In conditional analysis, the
signal from rs700635[C] was fully explained by either SVA-E[pos]
or rs1035142[T] whereas both SVA-E[pos] and rs1035142[T] re-
tained signiﬁcant associations when adjusted for rs700635[C]
(Supplementary Material, Table S1). SVA-E[pos] and rs1035142[T]
were also better able to explain the associated reduction in
Figure 1. Carriers of the rs700635[C] allele show preferential retention of CASP8 intron 8 sequences. RNA-seq data were obtained from normal prostate or breast tissue of
donorswhowere genotyped for rs700635. (A) Mediannormalized read counts (normalized for each individual to the total number of aligned reads) fromprostate RNAwere
stratiﬁed by rs700635 genotype and plotted over the genomic region covering the coding exons of CASP8. Data are from n = 6 C/C homozygotes (shown in red), n = 12 A/C
heterozygotes (shown in green) and n = 19 A/A homozygotes (shown in blue). The X-axis is the genomic position in Mb (GRCh37/hg19). The structure of RefSeq CASP8
transcripts in the region is shown beneath the X-axis. (B) Zoom showing prostate RNA median normalized read counts by genotype over the region extending from
the 3′ end of intron 7, through the 5′ region of intron 8 up to the NM_033358 variant exon. (C) Similarly plotted median normalized read counts from breast RNA. Data
are from n = 7 C/C homozygotes, n = 27 A/C heterozygotes and n = 22 A/A homozygotes. (D) Zoom showing breast RNA median-normalized read counts over a region
encompassing the 5′ region of CASP8 intron 8. (E) Association between rs700635 genotype and prostate RNA-seq read count in intron 8. For each individual, the
median of normalized RNA-seq read counts overlapping the 5′ region of intron 8 [chr2:202141827-202146555 (GRCh37/hg19)] was determined. Association with
genotype was then determined by linear regression against rs700635 variant allele count. P = 3.8 × 10−8 and β = 0.33 (SD units). (F) Similarly determined association
between rs700635 genotype and prostate RNA-seq read count over all major coding exons of CASP8. P = 0.678 and β =−0.07. (G) Association between rs700635 genotype
and breast RNA-seq read count in the 5′ region of intron 8. P = 3.11 × 10−11 and β = 0.36. (H) Association between rs700635 genotype and breast RNA-seq read count over
all CASP8 major coding exons. P = 0.0475 and β =−0.30.
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expression of themajorCASP8 isoforms observed previously (Sup-
plementary Material, Table S1). However, when we carried out a
similar analysis of blood RNA expression microarray data using
a probe from the NM_033358 variant exon (14), the strongest
expression quantitative trait locus mapped signiﬁcantly better to
rs700635 (Supplementary Material, Fig. S3B, Supplementary Ma-
terial, Table S1). The reason for this discrepancy is not clear, but
it suggests that genetic factors other than the SVA-E might affect
expression of the NM_033358 variant exon asmeasured by the ex-
pression microarrays.
We investigated potential mechanisms by which the SVA-E
might interfere with correct splicing of CASP8 intron 8. SVA-E
element insertions have been observed previously to create
anomalous splice junctions (15). However, in CASP8 RNA-seq
data fromblood, we did not detect anynew splice sites associated
with the presence of the SVA-E. No active splice donors or
acceptors were detected within the body of the SVA-E.
We had previously shown that at least some of the RNA se-
quences from intron 8 have paired ends spliced from upstream
CASP8 exons, which establishes that their transcriptional orienta-
tion is on the sense strand (7).Now,weexaminedmoredirectly the
possibility that the SVA-E might generate antisense transcripts
reading through the 5′ region of intron 8. We carried out RT-PCR
on blood RNA using orientation-speciﬁc primers in intron 8 for
ﬁrst-strand synthesis, followed by digital droplet PCR. In samples
where the SVA-E is present, sense transcripts through the 5′ region
of intron 8 were over 20-fold more abundant than antisense tran-
scripts (Supplementary Material, Fig. S4). Moreover, normalized
sense transcription through the region was signiﬁcantly related
to the presence of the SVA-E (P = 8.8 × 10−7). We also detected
substantial sense-strand transcription in the 3′ end of intron 7
(SupplementaryMaterial, Fig. S4, see also Fig. 1), raising the possi-
bility of cryptic promoter activation. However, intron 7 transcripts
did not vary in association with SVA-E genotype in blood RNA
(SupplementaryMaterial, Fig. S4F). Nevertheless, we can conclude
that intron 8 RNAs whose abundance is increased in association
with the SVA-E insertion are in the sense orientation with respect
to the CASP8 gene. This is in agreementwith our conclusions from
the RNA-seq data.
Discussion
A strength of our association studies based on WGS is that they
give a reasonably complete view of all SNPs and small indels pre-
sent in Icelanddown to a frequencyof∼0.05% (8).Moreover, the se-
quence data make possible a detailed analysis of associated
Figure 1 Continued
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structural variants, as we have done here. Using these methods,
we have found that the insertion of an SVA-E retrotransposon into
the CASP8 gene is associated with transcript anomalies and
protects against prostate cancer. SVA retrotransposons are rela-
tively young in evolutionary terms and the SVA-E family is
found only in humans, where it is thought to be highly active
Figure 2. rs700635[C] is associated with insertion of an SVA-E retrotransposon into the CASP8 gene. (A) The DNA sequence coverage of the CASP8 intron 8 region was
normalized and the median coverage for each genotype was plotted at each position. A copy number variation was detected in the region chr2:201281936-201284718
(GRCh38/hg38). Linear regression of mean normalized coverage by SNP genotype showed a signiﬁcantly higher copy number over this region in association with
rs700635[C] (P << 2 × 10−16). (B) The general structure of an SVA element: these non-autonomous retrotransposons consist of a CCCTCT repeat region (which may have
RNApolII promoter activity), followed by a series of Alu-like repeats, followed by a VNTR region, followed by a degenerate env gene fragment and long terminal repeat
from an extinct endogenous human retrovirus (HERV-K). Transcription in the SVA may utilize a polyadenylation signal within the long terminal repeat, or it may
continue into ﬂanking chromosomal sequences (see text). [Image from (17), used with permission.] (C) Boxplot showing association of DNA-sequence read pairs
spanning the SVA insertion site with rs700635 genotype: read pairs were selected such that the forward read was in CASP8 sequence within an interval of 1000 bp to
the left of the SVA-E insertion site and the paired reverse read was in CASP8 sequence within an interval of 1000 bp to the right of the SVA-E insertion site. Such reads
are expected to occur only if the SVA-E retrotransposon is absent. Counts of qualifying reads were normalized and plotted by genotype. Association was assessed by
linear regression of read count versus rs700635 genotype (P << 2 × 10−16).
Figure 3. The SVA-E insertion site in the CASP8 gene on chromosome 2 and the retrotransposition-transduction event on chromosome 19. Note that all structures are
drawn to preserve the genomic orientation of the CASP8 gene and the chr2 SVA-E insertion. Thus, the 5′ end of the SVA-E is to the right in the diagram and chr2
sequences are from the genomic forward strand. (A) The chr2 SVA-E (pale blue bars) is inserted into CASP8 intron 8 between the NM_033358 variant exon and exon 9
(at chr2:201281936-201284718). A copy of the SVA-E is present on chr19 (green bars). The chr19 SVA-E is ﬂanked by a transduced 288 bp segment, including the
NM_033358 variant exon, from chr2 (darker green bar). (B) The structure of the chr2 breakpoints: the left panel shows the breakpoint between the transduced
sequence and CASP8 intron 8 sequence. The central panel shows the left end of the SVA-E insertion on chr2 (blue bars) with the TSD sequence indicated. The
sequence of this junction is the same on the chr19 transduced copy (green bars). The right panel shows the breakpoint between the right end of the SVA-E and native
CASP8 intron 8 sequence with the TSD indicated. (C) The structure of the breakpoint between the transduced sequence and native chr19 sequence: the transduced
CASP8 intron 8 sequence contains a polyadenylation signal on the reverse strand (appearing here as TTTATT). Moving leftwards on the reverse strand, this is followed
by a short polyA sequence (hatched green bar) then a TSD derived from native chr19 sequence. (D) The breakpoint between the 5′ end of the SVA-E and native chr19
sequence, with the TSD sequence indicated. (E) The structure of the chr19 insertion site when the SVA-E is not present. Note that here the TSD sequence is unduplicated.
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(16). SVA insertions have been seen to cause gene disruption and
consequent disease (17). For example, the insertion of an SVA-E
into the 3′UTR of the FKTN gene disrupts the gene by creating an
anomalous splice junction, leading to Fukuyama muscular dys-
trophy (15). SVA elements oriented on the sense strand of the
genes into which they insert generally cause gene disruption by
thismechanism, or by the insertion of new promoters or polyade-
nylation signals (17, 18). In CASP8, however, the SVA-E is inserted
in the reverse orientation with respect to the gene and so it may
have a less extremeeffect. At least one caseof anSVAelement pro-
ducing antisense RNA has been documented before. In the SYNE2
gene, an intronic SVA-D appears to utilize an internal promoter to
produce antisense transcripts that terminate at a polyadenylation
signal in the adjacent intron (19). It is not known whether this
SYNE2 antisense RNA is pathogenic. Our study found that the
CASP8 SVA-E does not produce substantial amounts of antisense
RNA running through the 5′ region of intron 8. The transduction
events we observed suggest that such antisense RNAs, if pro-
duced, are prone to terminate at the polyadenylation site in CASP8
intron8non-coding strand sequence. If, as seems likely, theCASP8
SVA-E causes the splicing and transcriptional anomalies that we
observe, then mechanisms other than antisense transcription
from the inserted element are probable.
Variants that confer risk of some cancers and protect against
others have been observed before, for example in the TERT-
CLPTM1L locus (20). Satisfactory mechanistic explanations have
not been forthcoming. In addition to its apoptotic functions,
CASP8 has pleiotropic roles in necroptosis, inﬂammation, cell
survival and motility (1,2,21). The effects of disturbance of
CASP8 pathways might, therefore, vary between different tissue
and tumour types. The CASP8 SVA-E retrotransposon described
here is associated with increased risk of BCC and breast cancer,
but decreased risk of prostate cancer. Yet the associated CASP8
transcriptional anomalies are similar in all three corresponding
normal tissues and in breast and prostate cancers. This raises
provocative questions about the mechanism through which
CASP8 expression changes might be involved in the risk state
for these three diseases.
Materials and Methods
Subjects
Approval for the Icelandic study was granted by the Icelandic
National Bioethics Committee and the Icelandic Data Protection
Authority. All participants provided informed consent. Affected
individuals were identiﬁed through the ICR, which has main-
tained records of prostate cancer, breast cancer and melanoma
diagnoses since 1955. Controls consisted of individuals selected
from other ongoing association studies at deCODE who did not
have a diagnosis of the cancer in question recorded in the ICR.
In the Icelandic and non-Icelandic studies, it is not possible to
rigorously exclude that some male controls might have had
sub-clinical prostate cancer. Therefore, the effects we report
could be somewhat underestimated.
The Dutch prostate study population consisted of two recruit-
ment-sets of prostate cancer patients; Group A consists of 360
hospital-based patients recruited between January 1999 and
June 2006 at the urology outpatient clinic of the Radboud univer-
sitymedical center (Radboudumc); Group B consists of 1085 cases
recruited between June 2006 and December 2006 through a popu-
lation-based cancer registry held by the Netherlands Com-
prehensive Cancer Organization. The average age at diagnosis
for patients in Group A was 63 years (median, 63 years; range,
43–83 years). The average age at diagnosis for patients in Group
Bwas 65 years (median, 66 years; range, 43–75 years). The control
individuals were cancer free at recruitment andmatched for age.
They were recruited from within a population-based survey in
which 9371 individuals participated from a total of 22 500 age
and sex stratiﬁed, randomly selected inhabitants of Nijmegen
initially contacted. All participants were of self-reported Euro-
pean descent. The study protocol was approved by the Institu-
tional Review Board of Radboud University and all study
subjects gave written informed consent. Samples were geno-
typed on Illumina HumanHap300, HumanHapCNV370, Human-
Hap610, 1 M or Omni-Quad bead chips at the deCODE genetics
facility.
The Spanish study population consisted of prostate cancer
cases recruited from the Oncology Department of Zaragoza Hos-
pital in Zaragoza, Spain, from June 2005 to September 2008. All
patients were of self-reported European descent. Clinical infor-
mation including age at onset, grade and stage was obtained
from medical records. The average age at diagnosis for the pa-
tients was 69 years (median, 70 years) and the range was from
44 to 83 years. The control individuals were recruited at the Uni-
versity Hospital in Zaragoza and were cancer free at the time of
recruitment. Study protocols were approved by the Institutional
Review Board of Zaragoza University Hospital. All subjects gave
written informed consent.
In the UK, prostate cancer cases and controls were recruited
within the ‘Prostate Testing for Cancer and Treatment’ trial
(ProtecT) (22) and biological material collection was carried out
within the ‘Prostate Cancer: Mechanisms of Progression and
Treatment’ (ProMPT) study. Men aged 50–69 years were offered
an appointment for counseling and prostate-speciﬁc antigen
(PSA) testing. Recruitment took place at nine sites in the UK;
94 427 men agreed to participate in the study (50% of men con-
tacted) and 8807 (∼9%) had a raised PSA level. Of thosewith raised
PSA levels, 2022 (23%) were diagnosed with prostate cancer; 229
men (∼12%) had locally advanced (T3 or T4) or metastatic can-
cers, the rest having clinically localized (T1c or T2) disease. Men
with a PSA level of≥20 ng/mlwere excluded from the trial. For the
present study, 547 patients with PSA values >3 ng/ml and diag-
nosed with prostate cancer after undergoing a needle biopsy
(average age at diagnosis is 63 years). Controls were 1889 men
of average age 62 years with PSA values between 3 and 10 ng/
ml, but not diagnosed with prostate cancer after undergoing a
needle biopsy or with PSA values <3 ng/ml (and not biopsied).
Ethical approvals for the ProtecT and ProMPT studies were ob-
tained from Trent Multi-Centre Research Ethics Committee
(MREC/01/4/025 andMREC/01/4/061). All subjects gavewritten in-
formed consent prior to inclusion in the study.
The US prostate cancer cases were recruited from the Path-
ology Core of Northwestern University’s Prostate Cancer Specia-
lized Program of Research Excellence fromMay 2002 to May 2010.
The average age at diagnosis for the patients was 60 years (me-
dian, 59 years) and the rangewas from39 to 87 years. The controls
were recruited as healthy control subjects for genetic studies at
the University of Chicago and Northwestern University Medical
School, Chicago. All patients and controls were of self-reported
European descent. Study protocols were approved by the Institu-
tional Review Boards of Northwestern University and the Univer-
sity of Chicago. All subjects gave written informed consent.
The Romanian study population consisted of prostate cancer
cases recruited from the Urology Clinic ‘Theodor Burghele’ of The
University of Medicine and Pharmacy ‘Carol Davila’ Bucharest,
Romania, from May 2008 to November 2009. The average age at
diagnosis for the cases was 70 years (median, 71 years) and the
1014 | Human Molecular Genetics, 2016, Vol. 25, No. 5
 at U
niversity Library on June 14, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
range was from 46 to 89 years. The controls were recruited at the
General Surgery Clinic ‘St Mary’ and at the Urology Clinic ‘Theo-
dor Burghele’ of The University of Medicine and Pharmacy ‘Carol
Davila’ Bucharest, Romania. The average age for controls was 60
years (median, 62 years) with a range from 19 to 87 years. The
controls were cancer free at the time of recruitment. All subjects
were of self-reported European descent. Study protocols were ap-
proved by the National Ethical Board of the Romanian Medical
Doctors Association in Romania. All subjects gave written in-
formed consent.
Genotyping and association analysis
Procedures for whole-genome sequencing, Illumina SNP chip
genotyping, imputation and association testing have been de-
scribed previously (7,8,23). In this study, we used WGS informa-
tion from 8383 Icelanders to impute the genotypes of 150 656
Illumina chip-typed, long-range phased Icelanders and their un-
genotyped relatives. Single-track genotyping was done using
Centaurus assays (24). All genotyping was carried out at the de-
CODE genetics facility with standardized quality control and
allele calling protocols. We estimated the effective sample size
for each cohort as Ne cases and Ne controls with Ne = 2 × Na ×
Nc/(Na +Nc), which adjusts for the asymmetry in the number of
cases, Na, and controls, Nc. For Iceland we further adjusted Ne
for the relatedness of cases and controls by dividing by the gen-
omic inﬂation factor λg (=1.22 for prostate cancer).
RNA-seq analysis
RNA sequencing reads for 628 Icelandic blood samples were
aligned to Homo sapiens GRCh38/hg38 using TopHat (25) version
2.0.12 with a supplied set of known transcripts in GTF format
(RefSeq hg38). TopHat was conﬁgured such that it attempts ﬁrst
to align reads to the provided transcriptome then, for reads that
do not map fully to the transcriptome, it attempts to map
them onto the genome. Read mapping statistics used for read
count normalization were calculated using samtools version 1.1
(http://www.htslib.org). Mapped RNA-seq read data for 37 pros-
tate and 56 breast tissues from the GTEx Release phs000424.v4.
p1 from 17.01.2014 were downloaded from the GTEx consortium
(26) (http://www.gtexportal.org/home/) via dbGAP. TCGA data
from breast and prostate tumours were obtained from CGHub
(27).We used 1056 breast cancer and 374 prostate cancer samples
from the same numbers of participants, after ﬁltering for those
who had genotype data for rs6743068 (a surrogate marker of
rs700635) from corresponding samples.
Determination of association with DNA-seq coverage
over the SVA insertion region
In order to generate a plot of the median coverage of DNA
sequencing over the SVA-E insertion region, we counted
the number of reads covering each position in the interval
chr2:201230000–201290000 (GRCh38/hg38). We counted only
reads with an average PHRED-scaled base calling quality of ≥20,
those that were not marked as a duplicate, not clipped by ≥10
base pairs at both ends, and only the primary alignments. We
computed themean of local read counts over two intervals near-
by the SVA-E insertion site chr2:201230000–201280000 and
chr2:201285000–201290000 and used thismean for normalization
within each individual. We then computed the median of the
normalized read counts at every position in the interval
chr2:201230000–201290000 for each set of individuals with the
same SNP genotype. The resulting median normalized read
counts are shown in the plot in Figure 2A. In order to assess the
association between normalized read count and rs700635 geno-
type, the mean of the normalized coverage over the SVA-E inser-
tion interval (chr2:201281936–201284718) was determined for
each individual and then regressed against rs700635[C] allele
count (with the sequencing platform included as a covariate).
Analysis was based on 5253 whole-genome sequenced indivi-
duals taken from an earlier data freeze than the 8383 individuals
on whom the disease-association testing was based.
Determination of association between SNP genotype
and DNA sequence read pairs that detect the presence
or absence of the SVA-E retrotransposon
We used three strategies to assess the presence or absence of the
CASP8 SVA-E retrotransposon from whole-genome sequence
data. Firstly, we considered read pairs that span the SVA-E inser-
tion site, which should be observed only in the absence of the
retrotransposon. Read pairs were counted if the forward read
was in CASP8 sequence within an interval of 1000 bp to the left
of the SVA-E insertion site and the reverse read was in CASP8 se-
quence within an interval of 1000 bp to the right of the SVA-E in-
sertion site. Counts of qualifying reads were then normalized to
the mean of local read counts as described above. The boxplot in
Figure 2 shows these normalized read counts as a function of
genotype. Secondly, we considered read pairs that cross from
CASP8 sequence into the left end of an inserted SVA-E element.
In this case, read pairs were counted if the forward read was in
CASP8 sequence within an interval of 1000 bp to the left of the
SVA-E insertion site and the reverse read was in the SVA-E elem-
ent within 1000 bp of its left end. (Note here that we deﬁne the
‘left end’ of the SVA-E element as its 3′ end, because the retro-
transposon is inserted in an inverted orientation relative to the
CASP8 gene.) Counts of qualifying reads were normalized and
plotted by genotype as above. Thirdly, we considered read pairs
that cross from the right end of an inserted SVA-E element into
CASP8 sequence. In this case, read pairs were counted if the for-
ward read was in the SVA-E element and within 1000 bp of its
right end and the reverse read was in CASP8 sequences within
an interval extending 1000 bp to the right of the insertion site.
Counts of qualifying reads were normalized and plotted by geno-
type as above. We assessed the association between qualifying
read count and genotype by linear regression of normalized
qualifying reads against rs700635[C] allele count (with sequen-
cing platform and insert size included as covariates).
The chromosome 19 transduction event was identiﬁed by
reads crossing from the left end of the transduced chr2 sequence
into native chr19 sequence (see Fig. 3). Subsequently, we identi-
ﬁed a linked indel (at chr19: 46833095, GRCh38/hg38), which can
be used reliably to detect the presence of the chr19 transduction
event.We estimated a frequencyof∼0.213 for the chr19 transduc-
tion event in the Icelandic population. We also noted the pres-
ence of an SVA-E carrying transduced CASP8 intron 8 sequence
on an unmapped contig likely originating from chromosome 22
(chr22_KI270733v1_random). Due to its insertion into repetitive
genomic DNA sequence, this transduction event could not be
characterized further.
Genotyping the SVA-E
Wedetermined genotypes of the SVA-E usingmethods outlined
in (28). Brieﬂy, each individual may have one of three geno-
types: SS, a homozygous carrier of the SVA-E element; SD, a
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heterozygous carrier of the SVA-E and the deletion or DD, a
homozygous carrier of the deletion. For each individual i, the
input to the genotyping consists of two counts of reads pairs,
a count Bi of read pairs that span from the SVA-E across the
right breakpoint and a count Ci of reads that span the (empty)
insertion site. We compute the relative likelihood of the geno-
types as:
LðBi;CijSSÞ ¼ EjBij
LðBi;CijSDÞ ¼ 1=2ðjBijþjCijÞ
LðBi;CijDDÞ ¼ EjCij
Here, E is a constant, which we set to E = 0.001. Genotype
likelihoods were determined for a set of 8434 whole-genome se-
quenced Icelanders. The genotypes were then imputed into a set
of 150, 656 Icelanders using methods described previously (23).
PCR assay for the SVA-E
Two assayswere employed, onewhich detects the presence of the
SVA-E and a second which detects the empty insertion site. The
forward primer was the same for both assays: AATGGGGAG
GGATAGAGAGG. This primer is located to the left of the 288 bp
transduced region in CASP8 intron 8. For the SVA-E-present
assay, the reverse primer was CTGTGACCCTGCCAAATCC, located
within the left end of the SVA-E element. For the SVA-E-absent
assay, the reverse primer was TGTGGTCCATGAGTTGGTAGA,
located in CASP8 sequence to the right of the insertion site. PCR
products were resolved on agarose gels and scored manually.
Expression microarrays
Samples of total RNA from human peripheral blood (N = 1001)
were hybridized to Agilent Technologies Human 25 K microar-
rays as described previously (14). We quantiﬁed expression
changes between two samples as the mean logarithm (log10) ex-
pression ratio (MLR) comparedwith a reference pool RNA sample.
In comparing expression levels between groups of individuals
with different genotypes, we denoted the expression level for
each genotype as 10(average MLR), where the MLR is averaged over
individuals with the particular genotype.We determined the sig-
niﬁcance by regressing the MLR values against the number of
variant alleles carried. We took into account the effects of age,
gender and differential cell-type count in blood as explanatory
variables in the regression.
Strand-speciﬁc quantitative RT-PCR
Total RNAwas isolated fromwhole blood using Qiagen RNAMaxi
kits and the concentration and quality of the RNA was deter-
mined with Agilent 2100 Bioanalyzers (Agilent Technologies).
Orientation-speciﬁc ﬁrst-strand cDNA was synthesized using
the High Capacity cDNA Reverse Transcriptase kits (Life Tech-
nologies, Inc.). Primers were intron 8 forward: CCAGCAACTA
TTCTTATTCTACCATCA, intron 8 reverse: TGTAGAGCCTCTCTGG
TTCAATTTTA, intron 7 forward: CAGGAGGCCCAGGTATTGG,
intron 7 reverse: CACACAGGACCTCTCAGACTTCTG, each used
in separate reactions (500 nM ﬁnal concentration). Quantitation
was then carried out by digital PCR using both the forward
and reverse primers and ﬂuorescent labelled probes for
intron 8: 6FAM-ACAGGAAGTTTGTTTTCT-MGB and for intron
7: 6FAM-ACACTGACTTTACAACGATGG-MGB (Life Technologies)
on a Bio-Rad QX200™ AutoDG™ Droplet Digital™ PCR System.
Supplementary Material
Supplementary Material is available at HMG online.
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